Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165468 | 0.91 | LRRK2 (0.59) | METLRRK2RXFP1NPC1TP53 | |
| SCHEMBL167994 | 0.87 | LRRK2 (0.60) | METLRRK2CYP3A4SLCO1B1 | |
| SCHEMBL257184 | 0.85 | LRRK2 (0.64) | LRRK2KCNH2CYP3A4SLCO1B1 | |
| SCHEMBL167180 | 0.84 | PTGER1 (0.45) | TP53SMN1; SMN2ALDH1A1PTGER1MAPT | |
| SCHEMBL168763 | 0.83 | HCRTR1 (0.46) | SMN1; SMN2ALDH1A1KCNH2ABL1PTGER1 | |
| SCHEMBL256458 | 0.79 | LRRK2 (0.62) | METLRRK2 | |
| SCHEMBL168123 | 0.78 | LRRK2 (0.60) | METLRRK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL257191 | 0.77 | LRRK2 (0.63) | LRRK2KCNH2CYP3A4SLCO1B1 | |
| SCHEMBL166061 | 0.75 | HRH3 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1PTGER1 | |
| SCHEMBL21644610 | 0.75 | KDM1A (0.50) | METLRRK2NPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | claimed |
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2611772-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | LRRK2, PARK7, BRSK2 | MET 3646/4885LRRK2 1/4885RXFP1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.